Text size Jason Alden / Bloomberg Data on the Covid-19 vaccine in development by AstraZeneca and the University of Oxford published in The Lancet on Monday looked positive, but the stock fell after rising last week due to high expectations for the data. Shares of the US deposit receipt for …
Read More »
JP Morgan analysts downgraded the shares of Moderna Inc. MRNA, + 15.93% Neutral because of overweight by concerns about the valuation of the preclinical company, which has never produced an approved product. Moderna is developing a candidate for the COVID-19 vaccine that is widely considered to be one of the …
Read More »
As the Covid-19 crisis intensifies in the United States, the fight for an effective vaccine is about to collide with the electoral calendar. Pfizer (ticker: PFE) says it will seek authorization from the Food and Drug Administration for its Covid-19 vaccine starting in October. Meanwhile, the federal government’s Covid-19 vaccine …
Read More »
Moderna’s shares rose as much as 18% on Wednesday after the company announced that an early test of the coronavirus vaccine produced antibodies in all participants. A dose range induced immune responses in all 45 patients in the phase 1 trial and was “generally safe and well tolerated,” Moderna said …
Read More »
Text size It is good to be the Dow. The stock market continues to rise on Wednesday, but some indices are rising more than others. S&P 500 futures are up 1.4%, while Dow Jones Industrial Average futures are up 566 points, or 2.1%, and Nasdaq Composite is up just 0.5%. …
Read More »